menu

Blizard Institute

About menu

Two Blizard Institute Researchers Awarded Young Investigator Awards by the International Society for Chemotherapy and Cancer

Two Blizard Institute Researchers Awarded Young Investigator Awards by the International Society for Chemotherapy and Cancer

4 August 2015

news image

Jonathan Betts (Postdoctoral Research Assistant) and Lynette Phee (Honorary Clinical Lecturer), members of David Wareham’s group in the Centre for Immunobiology  have  been awarded Young Investigator Awards by the International Society for Chemotherapy and Cancer. This will enable them to present their work at the joint 2015 ICAAC/ICC conference in San Diego in September. ICAAC is the largest annual international meeting on antimicrobial resistance, chemotherapy and clinical infectious diseases with 2000 scientific presentations attended by more than 12,000 delegates. The ICC supports travel, accommodation and registration for a maximum of 10 early career researchers, following review of the quality, innovation and impact of the research submitted. Both Jonathan and Lynette received individual awards for work on the treatment of multi-drug resistant Gram-negative infections - outlined below. A link to all researchers successful in the ICC Young Investigator competition is available here

http://www.ischemo.org/awards/young-investigator-travel-awards

Jonathan Betts

Jonathan was born in 1981. He completed his PhD in Chemistry/Microbiology at the University of Hull currently a postdoctoral research scientist at Queen Mary, University of London.  Jonathan won this award for his abstract ‘In-vitro And In-vivo Activity Of ML302F A Novel Thioenolate Metallo-β-lactamase Inhibitor'

Lynette Phee

Lynette was born in 1981 and is currently a 4th year Specialist Trainee registrar in Clinical Microbiology with Barts Health / Homerton University Hospital NHS Trusts in London as well as a 2nd year PhD student with Queen Mary University of London.  Lynette won this award for her abstract ‘In Vitro and In Vivo Activity of Lactivicin Derivatives against Enterobacteriaceae Producing Extended-spectrum (ESBL) and Carbapenem hydrolysing β-lactamases’

 

 

Return to top